Corrigendum: Targeting complement pathways in polytrauma- And sepsis-induced multiple-organ dysfunction (Frontiers Media S.A. (2019) 10 (543) DOI: 10.3389/fimmu.2019.00543)

In the original article, we neglected to include a conflict of interest statement of Prof. John D. Lambris. JL is the founder of Amyndas Pharmaceuticals, which is developing complement inhibitors (including third-generation compstatin analogs, such as AMY-101) and is the inventor of patents or patent applications that describe the use of complement inhibitors for therapeutic purposes, some of which are developed by Amyndas Pharmaceuticals. JL is also the inventor of the compstatin technology licensed to Apellis Pharmaceuticals [i.e., 4(1MeW)7W/POT-4/APL-1 and PEGylated derivatives]. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.